Mayo Clinic | Strategic Alliance Partners

June 30, 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

June 25, 2021

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

June 22, 2021

Daniel H. Ahn, DO, shares how to navigate among the therapeutic options available for patients with advanced, unresectable hepatocellular carcinoma.

June 21, 2021

Jeremy C. Jones, MD, discusses the clinical utility of pembrolizumab in microsatellite instability–high colorectal cancer.

June 17, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the uptake of precision medicine in colorectal cancer.

June 17, 2021

Daniel H. Ahn, DO, discusses the utility of atezolizumab in combination with bevacizumab in hepatocellular carcinoma.

June 15, 2021

Jeremy C. Jones, MD, discusses the importance of testing for microsatellite instability high in colorectal cancer.

June 09, 2021

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.

June 07, 2021

Sikander Ailawadhi, MD, discusses the activity of lisaftoclax in patients with hematologic malignancies.

June 07, 2021

The novel BCL-2 inhibitor lisaftoclax elicited encouraging responses with acceptable tolerability in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma and other hematologic cancers.

May 18, 2021

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.

May 04, 2021

Stephen M. Ansell, MD, PhD, discusses challenges with positron emission tomography scans in patients with Hodgkin lymphoma.

April 01, 2021

Shaji K. Kumar, MD, discusses the evolving role of venetoclax in relapsed/refractory multiple myeloma.

March 30, 2021

The National Comprehensive Cancer Network guidelines for the management of frontline and relapsed/refractory multiple myeloma were updated to incorporate novel agents and combination strategies, providing a wide range of category 1 recommended therapies for patients.

March 25, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the challenges of utilizing chemotherapy-free regimens in colorectal cancer.

March 24, 2021

Donald W. Northfelt, MD, MS, FACP, discusses the progress made with CDK4/6 inhibitors in the treatment of patients with ER-expressing breast cancer and pivotal trials that have moved the needle forward.

March 12, 2021

Shaji K. Kumar, MD, discusses the challenges of selecting therapy for patients with heavily pretreated multiple myeloma.

March 04, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

March 01, 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

February 27, 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.